SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , April 8, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did not meet its primary endpoint of
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , March 12, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt , Ph.D., Chairman and Chief Executive Officer of United Therapeutics , will provide an overview and update on the company's
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , March 4, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond , Chief Financial Officer and Treasurer of United Therapeutics , will provide an overview and update on the company's business at
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 27, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2018 . "2018 was a truly transformative year for United Therapeutics .
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 20, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and annual 2018 financial results before the market opens on Wednesday, February 27, 2019 .
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Jan. 31, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that key data from the FREEDOM-EV study of Orenitram® (treprostinil) extended-release tablets were shared during an oral presentation at the Pulmonary
RESEARCH TRIANGLE PARK, N.C. , Jan. 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA). Under the agreement, United Therapeutics acquired
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Dec. 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt , Ph.D., Chairman and Chief Executive Officer of United Therapeutics , will provide an overview and update on the company's
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Nov. 29, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Health Canada has approved Pr Unituxin (dinutuximab for injection), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF),
- Arena will receive $800M upfront, and is eligible to receive low double-digit tiered royalties, plus up to $400M in milestone payments - United Therapeutics will receive exclusive, worldwide rights to ralinepag - a potential best-in-class agent for the treatment of pulmonary arterial hypertension
